Cardio-oncology & otherResearch article
Low cardiovascular event rates in patients treated with CAR T-cells: Real-world outcomes from two independent cohorts
- Real-world outcomes from two independent cohorts
- two large independent databases (DESTATIS (Germany) and the TriNetX network (US))
Authors' conclusion
Cardiovascular complications in CAR T-cell therapy were rare and primarily affected patients with preexisting cardiac conditions. Serious cardiac events were uncommon acutely but increased over time. The analysis underscores the need for risk-adapted follow-up and cardiological assessments to improve outcomes in patients with cardiac comorbidities. Inherent with the databases used, these results should be interpreted with caution, as underreporting and overreporting could introduce bias regarding risik factors and outcomes in both directions.
Study context
- Population
- Patients undergoing CD19- or BCMA-directed CAR T-cell therapyCAR T-cell cases from Germany and patients from the US · Germany (DESTATIS), CAR T-cell cases 2,545 · US (TriNetX), patients 1,335
Main finding
As reported in the abstract
Germany
51
events
US
20
events
Further findings
Early death
Cytokine release
- OR, patients with preexisting cardiac conditions
- OR 1.19, 95%CI 0.77-1.82
- no increased risk for immune-related complications
Neurotoxicity syndrome
- OR, patients with preexisting cardiac conditions
- OR 1.59, 95%CI 0.94-2.69
Major cardiovascular events · long-term
- OR, patients with preexisting cardiac conditions (higher risk)
- OR 1.89, 95%CI 1.23-2.91
Kidney failure · long-term
- OR, patients with preexisting cardiac conditions (higher risk)
- OR 2.98, 95%CI 1.85-4.81
Original publication
Summarised from the published abstract; every number is checked against it